Chimeric: Media Thread, page-615

Always nice when none holders take time out of their busy schedules to share their wisdom.

I disagree with your assertions but let's see what father time has instore for us.

Our Phase 1B CHM0201 +VACTOSERIB data could drop at some stage.

I'm expecting CHM 2101 Basket trial to kick off in the next couple of months. This is an ENORMOUS milestone, this trial has the potential to change the whole landscape. Preclinical data demonstrated complete eradication of tumor cells and no relapse of tumor cells. First in class targeting CDH17. The Basket trial addressing Gastric cancer (5th most common), colorectal cancer (3rd most common cancer) and Neuroendocrine tumors which in recent years has had a 6.5x increase.

Safety progress in ADVENT-AML trail and CHM2101.

Periodic updates on the progression of all 4 trials we'll have in the clinic, all addressing high unmet needs.

I agree with @dalts66. The opportunity the share price is currently presenting is a rare opportunity and I can only imagine that's why you are here.

This will start to rise throughout the year and personally I see 5-10 bags by this time next year.